K. V. Gorelov

K. V. Gorelov

Auto-generated profile, based on publicly available information

K. V. Gorelov

Federal Service for Surveillance in Healthcare

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2023 in Patient-Oriented Medicine and Pharmacy
Verified
Journal Article
Open access
PDF file
AKAlexander L. Khokhlov
Alexander L. Khokhlov
KGK. V. Gorelov
K. V. Gorelov
JRJ. V. Rybachkova
J. V. Rybachkova
The results and the degree of safety of hypoglycaemic drugs are presented. The current work analyses the safety of the use of sulfonylurea derivatives, biguanides, thiazolidinediones, meglitinides and α-glucosidase inhibitors according to clinical studies published in the scientific literature. Macrovascular complications in diabetes mellitus (DM) develop much earlier than microvascular complications and cause death in 75 % — 80 % of patients. The safety of hypoglycaemic therapy is assessed by the occurrence of hypoglycaemia, changes in body weight, effects on the gastrointestinal tract, and, of course, is associated with the risk of cardiovascular disease. In evaluating the results of numerous clinical studies, the use of sulfonylurea drugs (except gliclazide), meglitinides, alpha-glucosidase inhibitors (acarbose), and thiazolidinediones are not recommended in patients with a very high cardiovascular risk for treating type 2 diabetes due to evidence of an adverse effect on prognosis, or the presence of conflicting data or the lack of sufficient arguments for the cardiovascular safety of drugs. Metformin remains the preferred initial therapy with good tolerability.

30 September 2023 in "Medical & Pharmaceutical Journal "Pulse"
Verified
Journal Article
Closed access
EEEgiazarian E.A.
Egiazarian E.A.
KIKosova I.V.
Kosova I.V.
GKGorelov K.V.
Gorelov K.V.
One of the indicators of the effectiveness of the pharmacovigilance system is the number and quality of spontaneous reports of cases of adverse reactions (AR). It is important to receive spontaneous reports from both medical and pharmaceutical workers and from drug users in order to assess the true nature of the adverse reaction. This article discusses the problems of a limited number of spontaneous reports from patients and low awareness of the population on the safety and effectiveness of drugs in the countries of the Eurasian Economic Union (EAEU). The aim of this article was to analyze the attitude of drug users to the submission of spontaneous reports of adverse reactions to medications. To achieve this aim, a sociological study was conducted based on a survey of drug users. The study involved 800 drug users. This study found that in the EAEU countries, patients face adverse reactions or lack of effectiveness of therapy, but unlike the Russian Federation, consumers of the Republics of Belarus, Armenia and the Kyrgyz Republic don’t report this information to state regulatory authorities, pharmacy organizations, or manufacturers of medicines. Less than 20% of respondents know about filling out a notice of an adverse reaction or lack of therapeutic effect of a drug on the Roszdravnadzor website. In our opinion, the involvement of drug users in the spontaneous reporting system has many advantages and can help solve the current problem of underestimating data on adverse reactions.

7 June 2023 in Patient-Oriented Medicine and Pharmacy
Verified
Journal Article
Open access
PDF file
AKAlexander L. Khokhlov
Alexander L. Khokhlov
KGK. V. Gorelov
K. V. Gorelov
JRJ. V. Rybachkova
J. V. Rybachkova
The results and the degree of safety of various groups of hypoglycemic drugs are presented. The current work analyzes the safety of the use of glucagon-like peptide-1 (GLP-1) agonists, dipeptidyl peptidase-4 (iDPP-4) inhibitors, insulins, and inhibitors of sodium glucose cotransporter type 2 (iSGLT-2) according to clinical studies published in the scientific literature. Macrovascular complications in diabetes mellitus (DM) develop much earlier than microvascular complications and are the cause of death in 75–80% of patients. The safety of ongoing hypoglycemic therapy is based on the stabilization of its cardiovascular effect. GLP type 1 receptor agonists (lixisenatide) and DPP-4 idiopathic agonists (alogliptin) demonstrated a positive effect on the prognosis of patients with cardiovascular diseases. In addition to metformin, selective sodium-glucose cotransporter type 2 inhibitors, in particular empagliflozin and GLP type 1 analogs, act as first-line drugs from the position of cardiovascular safety in the treatment of patients with type 2 diabetes with a very high cardiovascular risk (liraglutide). The action of iSGLT-2 is glucose-dependent, which leads to a lower risk of hypoglycemia and, accordingly, cardiovascular safety for this class of drugs. Empagliflozin prevents the progression of cardiovascular disease in patients with type 2 diabetes, with heart failure with reduced ejection fraction, regardless of the presence of diabetes, providing a holistic approach to the management of patients with a cardiac profile.

5 October 2022 in Safety and Risk of Pharmacotherapy
Verified
Journal Article
Open access
PDF file
NVN. Yu. Velts
N. Yu. Velts
EZE. O. Zhuravleva
E. O. Zhuravleva
GKG. V. Kutekhova
G. V. Kutekhova
NTN. V. Tereshkina
N. V. Tereshkina
ALA. O. Lovkova
A. O. Lovkova
НВН. Ю. Вельц
Н. Ю. Вельц
Adverse drug reactions (ADRs) are recorded throughout the lifecycle of a medicinal product. In the post-marketing period, new ADRs are primarily identified via drug safety signals. In order to assess a signal and establish causality between an adverse drug reaction and a suspected medicinal product, it is necessary to evaluate the signal strength and quality.The aim of the study was to analyse the information submitted to Russian regulatory authorities by a patient and check it for a potential causal association of acute tubulointerstitial nephritis (ATIN) with the use of ceftriaxone and with the patient’s principal diagnosis, Lyme disease.Materials and methods: the authors analysed the patient’s submission received by the Ministry of Health of the Russian Federation in 2022 with a complaint that the treatment of Lyme disease with ceftriaxone had caused ATIN. The probability of a causal relationship between the medicinal product and the ADR was evaluated using the Naranjo algorithm.Results: according to the review of literature and the spontaneous reports collected in Pharmacovigilance 2.0, the database in the Automated Information System of the Russian Federal Service for Surveillance in Healthcare, both ceftriaxone and the underlying condition (Lyme disease) may cause renal abnormalities. Ceftriaxone is potentially nephrotoxic; it mainly affects the tubular system of the kidneys. Borreliosis may cause kidney damage as well; such damage manifests clinically as rapidly progressing and fatal damage to the glomeruli.Conclusions: the probability of a causal relationship between the development of ATIN in the complainant and the use of ceftriaxone was categorised as “possible”. However, the information available did not allow for establishing a definite relationship between kidney damage and the use of the medicinal product. Further monitoring of similar cases is necessary to minimise the risks of developing this pathology during treatment with ceftriaxone.

24 January 2023 in Safety and Risk of Pharmacotherapy
Verified
Journal Article
Open access
PDF file
ATA. R. Titova
A. R. Titova
NKN. V. Kosyakina
N. V. Kosyakina
TPT. S. Polikarpova
T. S. Polikarpova
YSYu. S. Skorodumova
Yu. S. Skorodumova
VPVitaly Polivanov
Vitaly Polivanov
KGK. V. Gorelov
K. V. Gorelov
Периодический обновляемый отчет по безопасности: обзор изменений

29 October 2024 in Safety and Risk of Pharmacotherapy
Verified
Journal Article
Open access
PDF file
ANA. V. Nechaev
A. V. Nechaev
SLS. A. Leshina
S. A. Leshina
AKA. G. Klepikova
A. G. Klepikova
LGL. A. Gaiderova
L. A. Gaiderova
OKO. G. Kornilova
O. G. Kornilova
НВН. Ю. Вельц
Н. Ю. Вельц
INTRODUCTION. Human immunoglobulins have been successfully used in clinical practice to treat multiple autoimmune and inflammatory conditions, and most of the current immunoglobulins are well tolerated by patients. However, patients may develop complications associated with proteins and other components of human plasma present in immunoglobulin products. The improvement of measures to ensure the quality, efficacy, and safety of immunobiologicals, including intravenous immunoglobulins (IVIGs), requires regular monitoring of data on individual and class-related adverse drug reactions (ADRs) associated with these medicinal products. AIM. This study aimed to conduct a systematic and comprehensive assessment of information on the potential ADRs to the IVIGs of Russian marketing authorisation holders from summaries of medicinal product characteristics (SmPCs) and the Russian national pharmacovigilance database. MATERIALS AND  METHODS.  The study analysed the SmPCs of all the IVIGs authorised for use in Russia and the spontaneous reports of ADRs to the IVIGs of Russian marketing authorisation holders. The study was limited to the spontaneous reports submitted to the database PHARMACOVIGILANCE/MONITORING OF CLINICAL TRIALS OF MEDICINES in the Automated Information System of the Federal Service for Surveillance in Healthcare from 1 January 2020 to 30 August 2024. RESULTS. At the time of the study, there were 20 normal human IVIGs authorised in Russia, and Russian companies held marketing authorisations for 9 of these IVIGs. During the study period, there were 133 cases of ADRs associated with the IVIGs of Russian marketing authorisation holders. The most common ADRs included 41 (16.5%) cases of hyperthermia, 14 (5.6%) cases of headache, 14 (5.6%) cases of urticaria, and 14 (5.6%) cases of treatment ineffectiveness. The majority of these cases (70%) occurred when IVIGs were used for approved indications. CONCLUSIONS. All the ADRs identified in the analysis of the Russian national pharmacovigilance database were expected and consistent with the ADRs labelled in the SmPCs of the reported IVIGs. To reduce the risk of ADRs and improve the safety of IVIG therapy, it is required to develop a comprehensive approach to human IVIGs with quality assurance measures and standard use guidelines.